03-312025

BioRay Reaches Overseas Licensing Deal for Three Biosimilars in Turkish Market

On March 31,BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that it has reached an agreement with a partner for the overseas commercialization of three independently developed drugs—infliximab, trastuzumab, and pertuzumab—in the Turkish market. This

read more

12-302024

BioRay’s BRY812 for Injection Granted FDA Approval for Clinical Trials

On December 30, 2024, BioRay Biopharmaceutical Co., Ltd (BioRay) announced that the application for the clinical trial of its proprietary BRY812 for injection, has been approved by the U.S. Food and Drug Administration (FDA).

read more

12-192024

BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives IND Acceptance from NMPA

On December 19, BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application for its self-developed Class 1 innovative therapeutic biological product, BR111 for i

read more

12-032024

BioRay Partners with UCB to Speed Up Launch of BIMZELX® in China

Recently, UCB China (“UCB”) and Zhejiang BioRay Pharmaceutical Co., Ltd (“BioRay”) have signed a commercialization agreement bring Bimekizumab (trade name: BIMZELX®) to patients across China. By leveraging the strengths of both parties, this collaboratio

read more

11-142024

Breakthrough for Domestic Innovative Drug: Phase III Clinical Study Results of Zuberitamab Published in Leading Oncology Journal

October 3, 2024 – The Phase III clinical trial results of Zuberitamab (trade name: Anruixi®), a Class I innovative therapeutic biological product developed by BioRay Pharmaceutical Co., Ltd.  (hereinafter referred to as "Bioray") , for the treatment of C

read more

09-202024

BioRay’s Adalimumab Injection Successfully Passes Colombia’s INVIMA GMP On-Site Inspection

On September 20th, the Adalimumab injection biosimilar developed by Bioray Pharmaceutical (Hangzhou) Co., Ltd., a subsidiary of Zhejiang BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as “BioRay”), successfully passed the GMP inspection by Colom

read more

12-132023

Zuberitamab Injection (Anruixi®), BioRay’s first self-developed CD20-targeted Type 1 innovative biological product, has been successfully included in the National Medical Insurance Drug List 2023

On December 13, BioRay Biopharmaceutical Co., Ltd. announced that Zuberitamab Injection (trade name: Anruixi®), its first self-developed and produced type 1 anti-CD20 innovative biological product, has been successfully included in the National Basic Medi

read more

12-122023

BioRay Biopharmaceuticals’ Adalimumab Biosimilar Approved for Marketing in Pakistan

On December 12, BioRay Biopharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that its adalimumab biosimilar, developed in-house by its wholly-owned subsidiary Hisun Biopharmaceutical Co., Ltd., and registered in Pakistan by its local p

read more

05-242023

BioRay Filed IND Application for BRY812, a Novel Antibody Drug Conjugate Targeting LIV-1

Shanghai, China, May 24, 2023 /PRNewswire/--BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that the Investigational New Drug (IND) application for the clinical trial of its proprietary BRY812, a novel antibody-drug conjugate

read more

05-172023

Zuberitamab (Anruixi®), the first domestically developed anti-CD20 antibody as a Class I innovative drug from BioRay Pharmaceutical, has been approved for marketing in China

Recently, BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as "Bioray") announced that its independently developed Class I innovative therapeutic biological product, Zuberitamab Injection (trade name: Anruixi®), indicated for the treatment of CD2

read more